Person looking into a microscope

Department of Brain Health News

The UNLV Department of Brain Health will advance research, education, and practice to benefit brain health and the care and treatment of people with brain disorders across the life span. Our faculty specialize in several areas that range from basic and clinical research in neurodegenerative disease, neuropsychology, and occupational therapy.

Current Brain Health News

Professor Ashkan Salamat in his lab at UNLV
Research | December 29, 2020

A yearlong collection of UNLV faculty making the news for their discoveries and contributions to the community.

brain scan imaging
Research | December 9, 2020

Although the COVID-19 pandemic has barred neuroscience Ph.D. student Andrew Ortiz from the lab, he continues to research diseases that affect millions of Americans.

man in front of El Camino car
People | September 9, 2020

Coming to UNLV at a most unusual time, President Keith E. Whitfield remains undaunted and ready to make his mark as a Rebel.

A portrait of UNLV's new president Keith Whitfield on campus.
Campus News | August 10, 2020

As summer heats up, so do the accomplishments on UNLV’s campus.

A scientist in a white lab coat rests his hand on his chin
Research | July 16, 2020

Dr. Jeffrey Cummings examines drug pipeline for treatments, and finds reason for optimism.

A UNLV banner on campus.
Campus News | July 2, 2020

A collection of news stories featuring the people and programs of UNLV.

Brain Health In The News

LABIOTECH.eu
December 21, 2020

Last week, AB Science reported successful results from a phase IIb/III clinical trial testing its drug masitinib in patients with mild to moderate symptoms of Alzheimer’s.

Market Screener
December 16, 2020

AB Science SA (NYSE Euronext – FR0010557264 – AB) will host a live webcast on December 17, 2020 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in Alzheimer’s Disease.

Yahoo!
December 16, 2020

AB Science SA (NYSE Euronext – FR0010557264 – AB) will host a live webcast on December 17, 2020 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in Alzheimer’s Disease.

HCP Live
December 8, 2020

A little more than a century ago, a German psychiatrist and neuropathologist by the name of Aloysius Alzheimer, MD, first described the pathology and symptoms of a disease known as presenile dementia at a 1906 meeting of the Southwest German Psychiatrists.

ALZFORUM
November 20, 2020

Will Biogen’s aducanumab become the first drug approved to slow progression of Alzheimer’s disease? Biogen’s licensing application for the biologic ran into headwinds at a U.S. Food and Drug Administration advisory committee meeting held November 6. It was led by the agency’s Billy Dunn, who directs development of new neurology treatments (Nov 2020 news). The agency’s internal biostatistical and neurologic reviews presented starkly opposing views of the efficacy data—the former critical, the latter glowing. This disconnect consternated both the committee and the many scientists listening to the public proceedings from around the country.

PR Newswire
November 18, 2020

Cognoptix, a leading diagnostics company dedicated to early detection of Alzheimer's disease (AD), announced today the formation of its new Scientific Advisory Board (SAB) with appointment of five world-class scientists and clinical researchers in AD. The SAB includes Jeffrey L. Cummings, MD, ScD; Lee E. Goldstein, MD, PhD; Philip Scheltens, MD, PhD; Martin R. Farlow, MD; and Carl H. Sadowsky, MD. Drs. Cummings and Goldstein will serve as SAB Clinical and Science Chairs, respectively.

Brain Health Experts

An expert in behavioral neuroscience with concentrations in Alzheimer's disease and schizophrenia.
A renowned expert on Alzheimer's Disease and other neurodegenerative disorders. 

Recent Brain Health Accomplishments

November 23, 2020
Arnold M. Salazar, Amanda M. Leisgang, Andrew A. Ortiz, and Jefferson W. Kinney (all Brain Health) published a paper titled, “Alterations of GABA B Receptors in the APP/PS1 Mouse Model of Alzheimer’s Disease” in the journal of Neurobiology of Aging. The paper describes the changes occurring in an Amyloid Beta mouse model of Alzheimer's disease ...
October 8, 2020
Jefferson Kinney (Brain Health) and James Hyman (Psychology) received a $1.2 million grant from the National Institutes of Aging to continue the research examining the link between Type II diabetes and Alzheimer’s disease. The grant will support them as they continue to investigate the mechanisms underlying Type II diabetes...
June 19, 2020
Dr. Jeffrey Cummings (Brain Health) recently published an article outlining a novel method for determining whether Alzheimer’s drug treatments in clinical trials are ready to move on to the next phase. The paper, “Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach,” was published in The Journal of Dementia...
May 11, 2020
Dr. Jeffrey Cummings (Brain Health) recently published an article, “The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs," in the Journal of Prevention of Alzheimer’s Disease. The somewhat provocative findings note that despite the trend toward prevention trials becoming more likely (in part because trials in...
April 29, 2020
Dr. Jeffery Cummings (Brain Health) and other members of a joint European Union/United States Task Force recently published, “Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease” in the Journal of Prevention of Alzheimer’s Disease. In recognition of the complexity of the disease, the task force acknowledges it may require...
April 10, 2020
Dr. Jeffrey Cummings (Brain Health), recently published an article, “An Actigraphy-Based Validation Study of the Sleep Disorder Inventory (SDI) in the Nursing Home" in Frontiers in Psychiatry. It studied the use of the SDI to identify disrupted sleep in dementia patients in nursing homes, which was proven to be useful when done properly...